TWI850390B - NF-κB誘導激酶之小分子抑制劑 - Google Patents

NF-κB誘導激酶之小分子抑制劑 Download PDF

Info

Publication number
TWI850390B
TWI850390B TW109118004A TW109118004A TWI850390B TW I850390 B TWI850390 B TW I850390B TW 109118004 A TW109118004 A TW 109118004A TW 109118004 A TW109118004 A TW 109118004A TW I850390 B TWI850390 B TW I850390B
Authority
TW
Taiwan
Prior art keywords
ethynyl
hydroxy
pyrimidin
phenyl
methylpyrrolidin
Prior art date
Application number
TW109118004A
Other languages
English (en)
Chinese (zh)
Other versions
TW202110842A (zh
Inventor
傑肯特 巴貝
文英 柴
溫蒂 艾寇斯
麥可 哈克
艾倫 赫曼
威廉 瓊斯
保羅 柯羅列克
凱文 柯魯特
艾利克 萊柏薩克
丹尼爾 皮普
亞歷山大 羅維拉
羅納德 沃林
Original Assignee
比利時商健生藥品公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 比利時商健生藥品公司 filed Critical 比利時商健生藥品公司
Publication of TW202110842A publication Critical patent/TW202110842A/zh
Application granted granted Critical
Publication of TWI850390B publication Critical patent/TWI850390B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/06—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW109118004A 2019-05-31 2020-05-29 NF-κB誘導激酶之小分子抑制劑 TWI850390B (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962855144P 2019-05-31 2019-05-31
US62/855,144 2019-05-31
US201962907833P 2019-09-30 2019-09-30
US62/907,833 2019-09-30

Publications (2)

Publication Number Publication Date
TW202110842A TW202110842A (zh) 2021-03-16
TWI850390B true TWI850390B (zh) 2024-08-01

Family

ID=71108552

Family Applications (2)

Application Number Title Priority Date Filing Date
TW109118004A TWI850390B (zh) 2019-05-31 2020-05-29 NF-κB誘導激酶之小分子抑制劑
TW113125993A TWI906955B (zh) 2019-05-31 2020-05-29 NF-κB誘導激酶之小分子抑制劑

Family Applications After (1)

Application Number Title Priority Date Filing Date
TW113125993A TWI906955B (zh) 2019-05-31 2020-05-29 NF-κB誘導激酶之小分子抑制劑

Country Status (37)

Country Link
US (2) US11254673B2 (enExample)
EP (2) EP4467199A3 (enExample)
JP (2) JP7547387B2 (enExample)
KR (1) KR20220027871A (enExample)
CN (2) CN118908957A (enExample)
AU (1) AU2020282005B2 (enExample)
BR (1) BR112021023796A2 (enExample)
CL (1) CL2021003142A1 (enExample)
CO (1) CO2021017838A2 (enExample)
CR (1) CR20210587A (enExample)
DK (1) DK3976597T3 (enExample)
DO (1) DOP2021000244A (enExample)
EC (1) ECSP21093623A (enExample)
ES (1) ES2989387T3 (enExample)
FI (1) FI3976597T3 (enExample)
HR (1) HRP20241352T1 (enExample)
HU (1) HUE068694T2 (enExample)
IL (1) IL288387B2 (enExample)
JO (1) JOP20210318B1 (enExample)
LT (1) LT3976597T (enExample)
MA (1) MA56038B1 (enExample)
MD (1) MD3976597T2 (enExample)
MX (1) MX2021014679A (enExample)
MY (1) MY205653A (enExample)
PE (1) PE20220768A1 (enExample)
PH (1) PH12021553011A1 (enExample)
PL (1) PL3976597T3 (enExample)
PT (1) PT3976597T (enExample)
RS (1) RS66105B1 (enExample)
SA (1) SA521430960B1 (enExample)
SG (1) SG11202112994WA (enExample)
SI (1) SI3976597T1 (enExample)
SM (1) SMT202400418T1 (enExample)
TW (2) TWI850390B (enExample)
UA (1) UA130430C2 (enExample)
UY (1) UY38721A (enExample)
WO (1) WO2020239999A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI906955B (zh) * 2019-05-31 2025-12-01 比利時商健生藥品公司 NF-κB誘導激酶之小分子抑制劑

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3141826A1 (en) 2019-05-31 2020-12-03 Ikena Oncology, Inc. Tead inhibitors and uses thereof
CA3142351A1 (en) 2019-05-31 2020-12-03 Ikena Oncology, Inc. Tead inhibitors and uses thereof
CA3257152A1 (en) * 2022-05-11 2023-11-16 Janssen Pharmaceutica Nv Pyrrolidine derivatives useful as NF-κB induction kinase inhibitors
US20250304567A1 (en) * 2022-05-11 2025-10-02 Janssen Pharmaceutica Nv Pyrrolidione derivatives as inhibitors of nf kappa b inducing kinase
AU2023410324A1 (en) 2022-12-22 2025-05-15 Boehringer Ingelheim International Gmbh Crystalline forms of a her2 inhibitor
WO2025020886A1 (zh) * 2023-07-27 2025-01-30 浙江星浩澎博医药有限公司 氮杂喹唑啉环衍生物及其用途
CN121568696A (zh) 2023-07-28 2026-02-24 勃林格殷格翰国际有限公司 制备her2抑制剂的方法
WO2025235874A1 (en) * 2024-05-10 2025-11-13 Schrödinger, Inc. Heterocyclics as egfr inhibitors
WO2026029041A1 (ja) * 2024-07-30 2026-02-05 日本たばこ産業株式会社 ピラゾロピリミジン化合物及びその医薬用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200605886A (en) * 2004-08-03 2006-02-16 Wyeth Corp Indazoles useful in treating cardiovascular diseases
WO2009158011A1 (en) * 2008-06-26 2009-12-30 Amgen Inc. Alkynyl alcohols as kinase inhibitors
WO2012123522A1 (en) * 2011-03-16 2012-09-20 F. Hoffmann-La Roche Ag 6,5-heterocyclic propargylic alcohol compounds and uses therefor
WO2018037058A1 (en) * 2016-08-24 2018-03-01 F. Hoffmann-La Roche Ag 2-azabicyclo[3.1.0]hexan-3-one derivatives and methods of use

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9930616D0 (en) 1999-12-24 2000-02-16 Mathilda & Terence Kennedy Ins Activation and inhibition of the immune system
US7132428B2 (en) 2003-07-03 2006-11-07 Aventis Pharmaceuticals Inc. Pyrazoloisoquinoline derivative as kinase inhibitors for the treatment of various disorders
WO2006053277A2 (en) 2004-11-12 2006-05-18 Chippac, Inc. Wire bond interconnection
US20110183975A1 (en) 2008-10-07 2011-07-28 Yasuhiro Goto Novel 6-azaindole aminopyrimidine derivatives having nik inhibitory activity
US9034866B2 (en) 2012-02-17 2015-05-19 Genentech, Inc. Tricyclic compounds and methods of use therefor
US8859553B2 (en) 2012-07-30 2014-10-14 Astar Biotech Llc Protein kinase inhibitors
TWI663166B (zh) 2013-04-24 2019-06-21 健生藥品公司 新化合物
CN105658639A (zh) * 2013-08-22 2016-06-08 豪夫迈·罗氏有限公司 炔基醇和应用方法
JP2016533385A (ja) 2013-08-22 2016-10-27 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ アルキニルアルコール及び使用方法
TWI704146B (zh) 2013-09-26 2020-09-11 比利時商健生藥品公司 用作ＮＩＫ抑制劑之新的1-(４-嘧啶基)-１Ｈ-吡唑並[３,２-ｃ]吡啶衍生物
TWI627173B (zh) 2013-09-26 2018-06-21 比利時商健生藥品公司 作為ＮＩＫ抑制劑的新穎３－（１Ｈ－吡唑－４－基）－１Ｈ－吡咯并［２，３－ｃ］吡啶衍生物
EP3209654B1 (en) 2014-10-23 2018-10-03 Janssen Pharmaceutica N.V. New pyrazole derivatives as nik inhibitors
CA2960336C (en) 2014-10-23 2023-03-07 Janssen Pharmaceutica Nv Compounds as nik inhibitors
EA033238B1 (ru) 2014-10-23 2019-09-30 Янссен Фармацевтика Нв Новые производные тиенопиримидина в качестве ингибиторов nik
KR102523405B1 (ko) 2014-10-23 2023-04-18 얀센 파마슈티카 엔.브이. Ｎｉｋ 억제제로서의 신규 피라졸로피리미딘 유도체
WO2016135163A1 (en) 2015-02-25 2016-09-01 F. Hoffmann-La Roche Ag Alkynyl alcohols and methods of use
JP6910359B2 (ja) 2016-01-22 2021-07-28 ヤンセン ファーマシューティカ エヌ．ベー． Ｎｉｋ阻害剤としての新たな置換されたシアノインドリン誘導体
KR102720461B1 (ko) 2016-01-22 2024-10-21 잔센파마슈티카엔.브이. Nik 억제제로서의 신규 6원 헤테로방향족 치환된 시아노인돌린 유도체
ES2805976T3 (es) 2016-06-30 2021-02-16 Janssen Pharmaceutica Nv Derivados heteroaromáticos en calidad de inhibidores de NIK
WO2018002219A1 (en) 2016-06-30 2018-01-04 Janssen Pharmaceutica Nv Cyanoindoline derivatives as nik inhibitors
JP7140751B2 (ja) 2016-08-24 2022-09-21 エフ．ホフマン－ラ ロシュ アーゲー ２－アザビシクロ［３．１．０］ヘキサン－３－オン誘導体及び使用方法
KR102662373B1 (ko) 2017-07-06 2024-04-29 얀센 파마슈티카 엔브이 Nik 억제제로서의 신규 치환 아자인돌린 유도체
CN109810110B (zh) * 2017-11-22 2023-01-24 中国科学院上海药物研究所 一种具有2-氨基嘧啶结构的化合物，其制备方法和用途
CA3141826A1 (en) 2019-05-31 2020-12-03 Ikena Oncology, Inc. Tead inhibitors and uses thereof
SG11202112391UA (en) 2019-05-31 2021-12-30 Sage Therapeutics Inc Neuroactive steroids and compositions thereof
CA3142351A1 (en) 2019-05-31 2020-12-03 Ikena Oncology, Inc. Tead inhibitors and uses thereof
UA130430C2 (uk) * 2019-05-31 2026-02-18 Янссен Фармацевтика Нв НИЗЬКОМОЛЕКУЛЯРНІ ІНГІБІТОРИ КІНАЗИ, ЩО ІНДУКУЄ NF-kB
CA3139018A1 (en) 2019-05-31 2020-12-03 Chiesi Farmaceutici S.P.A. Amino quinazoline derivatives as p2x3 inhibitors
PE20221038A1 (es) 2019-09-30 2022-06-17 Incyte Corp Compuestos de pirido[3,2-d] pirimidina como inmunomoduladores

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200605886A (en) * 2004-08-03 2006-02-16 Wyeth Corp Indazoles useful in treating cardiovascular diseases
WO2009158011A1 (en) * 2008-06-26 2009-12-30 Amgen Inc. Alkynyl alcohols as kinase inhibitors
WO2012123522A1 (en) * 2011-03-16 2012-09-20 F. Hoffmann-La Roche Ag 6,5-heterocyclic propargylic alcohol compounds and uses therefor
WO2018037058A1 (en) * 2016-08-24 2018-03-01 F. Hoffmann-La Roche Ag 2-azabicyclo[3.1.0]hexan-3-one derivatives and methods of use

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI906955B (zh) * 2019-05-31 2025-12-01 比利時商健生藥品公司 NF-κB誘導激酶之小分子抑制劑

Also Published As

Publication number Publication date
ECSP21093623A (es) 2022-01-31
TW202110842A (zh) 2021-03-16
ES2989387T3 (es) 2024-11-26
MA56038A (fr) 2022-04-06
DK3976597T3 (da) 2024-09-09
LT3976597T (lt) 2024-10-10
HUE068694T2 (hu) 2025-01-28
SMT202400418T1 (it) 2024-11-15
US11827634B2 (en) 2023-11-28
DOP2021000244A (es) 2022-04-18
CN118908957A (zh) 2024-11-08
IL288387B2 (en) 2026-01-01
TWI906955B (zh) 2025-12-01
HRP20241352T1 (hr) 2024-12-20
SA521430960B1 (ar) 2024-11-12
JP2022534302A (ja) 2022-07-28
JOP20210318B1 (ar) 2025-10-01
CR20210587A (es) 2022-02-11
US20210300918A1 (en) 2021-09-30
EP4467199A3 (en) 2025-03-05
IL288387A (en) 2022-01-01
IL288387B1 (en) 2025-09-01
CO2021017838A2 (es) 2022-01-17
MX2021014679A (es) 2022-04-06
UA130430C2 (uk) 2026-02-18
AU2020282005A1 (en) 2021-12-23
CN114222737A (zh) 2022-03-22
PT3976597T (pt) 2024-10-22
KR20220027871A (ko) 2022-03-08
CA3143350A1 (en) 2020-12-03
CL2021003142A1 (es) 2022-08-19
MA56038B1 (fr) 2024-11-29
JOP20210318A1 (ar) 2023-01-30
SI3976597T1 (sl) 2024-11-29
JP2024167319A (ja) 2024-12-03
US11254673B2 (en) 2022-02-22
BR112021023796A2 (pt) 2022-02-08
PH12021553011A1 (en) 2022-11-07
EP3976597A1 (en) 2022-04-06
WO2020239999A1 (en) 2020-12-03
EP4467199A2 (en) 2024-11-27
JP7547387B2 (ja) 2024-09-09
SG11202112994WA (en) 2021-12-30
MY205653A (en) 2024-11-02
PE20220768A1 (es) 2022-05-16
UY38721A (es) 2020-11-30
FI3976597T3 (fi) 2024-09-25
MD3976597T2 (ro) 2025-01-31
PL3976597T3 (pl) 2024-12-16
CN114222737B (zh) 2024-07-26
US20240199605A1 (en) 2024-06-20
EP3976597B1 (en) 2024-08-28
RS66105B1 (sr) 2024-11-29
AU2020282005B2 (en) 2026-02-12
US20230080834A1 (en) 2023-03-16
TW202517638A (zh) 2025-05-01

Similar Documents

Publication Publication Date Title
TWI850390B (zh) NF-κB誘導激酶之小分子抑制劑
EP4067347B1 (en) Heterocyclic inhibitors of cbp/ep300 for the treatment of cancer
CN107438593B (zh) 治疗化合物及其用途
KR20250093570A (ko) Sos1 억제제
CN107108512A (zh) 治疗性化合物及其用途
JP2019516759A (ja) がんの処置のためのピラゾロピリジン誘導体
CN107531690A (zh) 用作CBP和/或EP300抑制剂的4,5,6,7‑四氢‑1H‑吡唑并[4,3‑c]吡啶‑3‑胺化合物
CN111320624B (zh) 三唑并吡啶类和咪唑并吡啶类化合物及其制备方法和医药用途
US12617789B2 (en) Small molecular inhibitors of NF-κb inducing kinase
HK40119602A (en) Small molecule inhibitors of nf-kb inducing kinase
CN110612302B (zh) 作为激酶JAK抑制剂的吡唑并[1,5-a]嘧啶衍生物
HK40079501A (en) Heterocyclic inhibitors of cbp/ep300 and their use in treatment of cancer
EA045720B1 (ru) НИЗКОМОЛЕКУЛЯРНЫЕ ИНГИБИТОРЫ NF-κB-ИНДУЦИРУЮЩЕЙ КИНАЗЫ
HK40071178B (en) Small molecule inhibitors of nf-kb inducing kinase
HK40071178A (en) Small molecule inhibitors of nf-kb inducing kinase
WO2026002176A1 (zh) 作为wrn抑制剂的含芳香环化合物及其应用
HK40005958B (zh) 用於治疗癌症的吡唑并吡啶衍生物
HK1243073B (zh) 治療性化合物及其用途
HK1247614B (zh) 治療化合物及其用途
HK40005957A (en) Heterocyclic inhibitors of cbp/ep300 and their use in the treatment of cancer
HK40005957B (en) Heterocyclic inhibitors of cbp/ep300 and their use in the treatment of cancer
HK1248696B (zh) 治療性噠嗪化合物及其用途
HK1248695B (zh) 用作cbp和/或ep300抑制劑的4，5，6，7-四氫-1h-吡唑並[4，3-c]吡啶-3-胺化合物